Septerna (SEPN) Stock Forecast & Price Target

$10.41 +0.13 (+1.26%)

As of 06/12/2025 04:00 PM Eastern

Septerna - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 4 Analyst Ratings

Sell
0

Hold
1

Buy
3

Based on 4 Wall Street analysts who have issued ratings for Septerna in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for SEPN.

Consensus Price Target

$27.00
159.37% Upside

According to the 4 analysts' twelve-month price targets for Septerna, the average price target is $27.00. The highest price target for SEPN is $38.00, while the lowest price target for SEPN is $18.00. The average price target represents a forecasted upside of 159.37% from the current price of $10.41.

Get the Latest News and Ratings for SEPN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Septerna and its competitors.

SEPN Analyst Ratings Over Time

Type	Current Forecast 6/13/24 to 6/13/25	1 Month Ago 5/14/24 to 5/14/25	3 Months Ago 3/15/24 to 3/15/25	1 Year Ago 6/14/23 to 6/13/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$27.00	$33.00	$34.00	N/A
Forecasted Upside	159.37% Upside	224.80% Upside	439.68% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	N/A

SEPN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SEPN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Septerna Stock vs. The Competition

Type	Septerna	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	159.37% Upside	5,820.88% Upside	13.02% Upside
News Sentiment Rating	Very Positive News See Recent SEPN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/16/2025	Cantor Fitzgerald 3 of 5 stars	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$20.00 ➝ $25.00	+153.16%
5/16/2025	Wells Fargo & Company 3 of 5 stars	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $18.00	+71.69%
11/19/2024	JPMorgan Chase & Co. 2 of 5 stars		Initiated Coverage	Overweight	$38.00	+61.36%
11/19/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Werber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:41 AM ET.

Should I Buy Septerna Stock? SEPN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 26, 2025. Please send any questions or comments about these Septerna pros and cons to contact@marketbeat.com.

Septerna
Bull Case

Here are some ways that investors could benefit from investing in Septerna, Inc.:

Recent insider buying activity, including a significant purchase by Director Alan Ezekowitz, indicates confidence in the company's future performance. This can be a positive signal for potential investors.
Septerna, Inc. reported earnings that exceeded analysts' expectations, with an EPS of ($0.64) compared to the consensus estimate of ($0.69). This suggests that the company is performing better than anticipated.
The company has a promising pipeline focused on G protein-coupled receptor therapies, which are critical in treating various diseases, including those in endocrinology and immunology. This positions Septerna, Inc. well in the biotechnology sector.
As of the latest trading session, the stock price is $9.19, which is significantly higher than its one-year low of $4.17, indicating a potential recovery and growth opportunity for investors.
Institutional investment interest has increased, with Soleus Capital Management L.P. acquiring 675,409 shares, reflecting growing confidence from larger investors in Septerna's potential.

Septerna
Bear Case

Investors should be bearish about investing in Septerna, Inc. for these reasons:

The company has reported a negative EPS for the current fiscal year, with analysts expecting an EPS of -7.11, indicating ongoing financial challenges.
Despite recent positive earnings, the company missed analysts' expectations in its latest quarter, reporting an EPS of ($0.49) against a consensus of ($0.38), which may raise concerns about its ability to meet future targets.
Septerna's stock has experienced volatility, with a significant drop of 3.1% in a recent trading session, which could deter risk-averse investors.
The biotechnology sector can be highly unpredictable, and Septerna, Inc. is still in the clinical stage, meaning it faces risks related to product development and regulatory approvals.
With a 50-day moving average of $6.73 and a 200-day moving average of $13.82, the stock's current price is below both averages, suggesting a bearish trend that may concern potential investors.

SEPN Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Septerna is $27.00, with a high forecast of $38.00 and a low forecast of $18.00.
: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Septerna in the last twelve months. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SEPN shares.
: According to analysts, Septerna's stock has a predicted upside of 159.37% based on their 12-month stock forecasts.
: Septerna has been rated by research analysts at Cantor Fitzgerald, and Wells Fargo & Company in the past 90 days.
: Analysts like Septerna less than other "medical" companies. The consensus rating score for Septerna is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how SEPN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:SEPN) was last updated on 6/13/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Stock Forecast & Price Target